BioPharma Resources

Investigational drug · Phase 3

CMP 001

Also called: Vidutolimod

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Malignancies, NSCLC, Ovarian Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

1

Any phase or sponsor naming "CMP 001"

First trial start

2021

Sep 29, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CMP 001", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Malignancies
  • NSCLC
  • Ovarian Cancer
  • Urothelial Cancer
  • Solid Tumors
  • Locally Advanced Basal Cell Carcinoma

Approved drugs for the same conditions: Non-small cell lung cancer · Ovarian cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "CMP 001" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 22 on PubMed

Also in development for Advanced Malignancies

  • LBL-007AlcestobartPhase 38 trials

    BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer

  • GimistotugBGB-A445Phase 34 trials

    BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma

  • PelabresibDAK539, CPI-0610Phase 34 trials

    Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)

  • TQB2930Phase 34 trials

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer

  • TQB3616Phase 34 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer

  • BGB-15025Phase 33 trials

    BeOne Medicines (BeiGene) · Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Advanced Malignancies

  • SurzebiclimabBGB-A425Phase 33 trials

    BeOne Medicines (BeiGene) · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion

  • OciperlimabBGB-A1217Phase 32 trials

    BeOne Medicines (BeiGene) · Non Small Cell Lung Cancer, Advanced Malignancies

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.